GURU - ETF AI Analysis
Top Page
Global X Guru Index ETF (GURU)
Rating:68Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains so far this year and over the past few months, indicating positive recent momentum.
Sector Diversification
Holdings are spread across several sectors like health care, technology, industrials, and consumer-related areas, which helps reduce the impact of weakness in any single industry.
Multiple Strong-Contributing Holdings
Several top positions, including companies like Avis Budget and other technology and health care names, have delivered strong year-to-date results that support the fund’s overall performance.
Negative Factors
High Expense Ratio
The fund charges a relatively high management fee, which can eat into long-term returns compared with lower-cost ETFs.
Heavy U.S. Concentration
Almost all of the ETF’s assets are invested in U.S. companies, offering very limited geographic diversification.
Exposure to Lagging Holdings
A few notable positions, such as AppLovin and Expedia, have shown weak or negative year-to-date performance, which can drag on the fund if the trend continues.
GURU vs. SPDR S&P 500 ETF (SPY)
AUM62.56M
RegionNorth America
Expense Ratio0.75%
Beta0.99
IssuerGlobal X
Inception DateJun 04, 2012
Dividend Yield0.1%
Asset ClassEquity
Index TrackedSolactive Guru Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume817
30 Day Avg. Volume1,420
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
84.14Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering88
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GURU Summary
The Global X Guru Index ETF (GURU) follows the Solactive Guru Index, which copies the top stock picks of well-known hedge fund managers based on their public filings. It holds a mix of U.S. companies across many sectors, with a focus on health care and technology, and includes familiar names like Amazon and Expedia. Someone might invest in GURU to get diversified exposure to the broader stock market while piggybacking on the research of professional investors. A key risk is that these hedge fund picks can still be wrong, so the ETF’s price can go up and down with the market.
How much will it cost me?The Global X Guru Index ETF (Ticker: GURU) has an expense ratio of 0.75%, which means you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because it is actively managed, aiming to replicate the strategies of top hedge fund managers rather than passively tracking a broad market index.
What would affect this ETF?The Global X Guru Index ETF (GURU) could benefit from positive trends in sectors like Health Care and Technology, which are heavily weighted in its portfolio and often driven by innovation and consumer demand. However, economic uncertainty, rising interest rates, or regulatory changes affecting hedge fund strategies could negatively impact the ETF's performance, as it relies on replicating hedge fund holdings primarily focused on U.S. markets. Investors should also consider the potential volatility in top holdings like Tesla and Alibaba, which are sensitive to global market conditions and sector-specific challenges.
GURU Top 10 Holdings
GURU is leaning heavily into U.S. health care and tech, with a bench full of biotech names that make the ride a bit bumpy. Astera Labs and Lam Research look like key engines, rising on the back of AI and chip demand and giving the fund some much-needed tech muscle. On the health care side, Corcept and Travere are pulling their weight, but early-stage players like Immunovant and Arcutis are more of a roller coaster, occasionally dragging on returns as investors wrestle with cash burn and clinical risk.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Apogee Therapeutics | 1.79% | $1.12M | $10.10B | 249.99% | 49 Neutral | |
| Astera Labs, Inc. | 1.77% | $1.10M | $62.01B | 281.36% | 68 Neutral | |
| Corcept Therapeutics | 1.73% | $1.08M | $9.71B | 22.95% | 76 Outperform | |
| Immunovant | 1.54% | $962.27K | $7.96B | 123.92% | 45 Neutral | |
| Natera | 1.49% | $932.50K | $39.05B | 86.91% | 73 Outperform | |
| Kymera Therapeutics | 1.48% | $926.34K | $9.22B | 150.76% | 56 Neutral | |
| Arcutis Biotherapeutics | 1.41% | $881.35K | $3.35B | 80.04% | 60 Neutral | |
| Travere Therapeutics | 1.40% | $875.99K | $5.31B | 240.58% | 56 Neutral | |
| SanDisk Corp | 1.39% | $868.36K | $260.32B | 3804.74% | 55 Neutral | |
| United Airlines Holdings | 1.37% | $856.29K | $39.06B | 36.74% | 74 Outperform |
GURU Technical Analysis
Positive
―
Price Trends
67.09
Positive
64.30
Positive
63.00
Positive
Market Momentum
0.61
Positive
53.59
Neutral
37.27
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GURU, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 68.88, equal to the 50-day MA of 67.09, and equal to the 200-day MA of 63.00, indicating a neutral trend. The MACD of 0.61 indicates Positive momentum. The RSI at 53.59 is Neutral, neither overbought nor oversold. The STOCH value of 37.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GURU.
GURU Peer Comparison
Comparison Results
Performance Comparison
GURU
Global X Guru Index ETF
68.80
14.04
25.64%
BAMD
Brookstone Dividend Stock ETF
―
―
―
SOVF
Sovereign's Capital Flourish Fund
―
―
―
STNC
Stance Equity ESG Large Cap Core ETF
―
―
―
FDRS
Founder-Led ETF
―
―
―
YALL
God Bless America ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents